Every one of those 2 sits in a single category, health-it. DataMEDS AI, Inc. is most often covered alongside EinsteinRx, which appears in 2 of these 2 stories. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about DataMEDS AI, Inc.
Every one of those 2 sits in a single category, health-it. DataMEDS AI, Inc. is most often covered alongside EinsteinRx, which appears in 2 of these 2 stories. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 5.3. We currently track 2 Healthcare stories that mention DataMEDS AI, Inc., published between August 12, 2026 and August 13, 2026.
Stories tracked
2
Sources per story
2
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 58 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering DataMEDS AI, Inc.. Shared-story counts are live from our verified record — not editorial picks.
DataMeds AI (NASDAQ:MEDS) is separating its pharmacy operations under a newly named Corexa Health division, with Corexa Pharmacy and Corexa Tech & Hub as subsidiaries. The move lays groundwork for vertical integration across pharmacy, telemedicine, and diagnostic lab services.
Health IT firm DataMeds AI uses its EinsteinRx AI and PharmacyChain blockchain platforms to power a direct-to-consumer pharmacy launch of Long COVID supplements, with a market projected to reach $32.8B. A pending acquisition of the product maker adds vertical integration.